Expression and clinical significance of microRNA‑21, PTEN and p27 in cancer tissues of&nbsp;patients with non‑small cell lung cancer

Yang,Ling; Yang,Jihong

doi:10.3892/ol.2020.11910

Expression and clinical significance of microRNA‑21, PTEN and p27 in cancer tissues of patients with non‑small cell lung cancer

Authors:
- Ling Yang
- Jihong Yang
View Affiliations

Affiliations: Department of Chest Medicine Oncology, Hubei Cancer Hospital, Wuhan, Hubei 430079, P.R. China, School of Life Science, Huazhong Normal University, Wuhan, Hubei 430079, P.R. China
Published online on: July 24, 2020 https://doi.org/10.3892/ol.2020.11910
Article Number: 49
Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Expression and clinical significance of micro‑RNA‑21, PTEN and p27 in cancer tissue of patients with non‑small cell lung cancer (NSCLC) were investigated. In this study, cancer tissue and adjacent tissue specimens from 230 patients with NSCLC were collected from thoracic surgery department in Hubei Cancer Hospital from March 2010 to February 2016. The expression of miRNA‑21, PTEN and p27 in cancer tissue and adjacent tissue of patients with NSCLC was detected by RT‑PCR. Combined with clinical information, the correlation among miRNA‑21, PTEN, p27 and clinical features of NSCLC was analyzed. The expression of miRNA‑21, PTEN, p27 in NSCLC was significantly lower than that in adjacent tissue by RT‑PCR (P<0.05). There was no significant difference in age, sex and course of disease (P>0.050), but there were differences in smoking, lymph node metastasis, TNM stage and differentiation degree classification (P<0.050). By comparing the 3‑year survival rate in the group with high and low expression of miRNA‑21, PTEN and p27, it was found that the 36‑month survival rate of patients with high expression of miRNA‑21 was 85.19% (P<0.05), and of patients with low expression of miRNA‑21 it was 95.90% (P<0.05). The 36‑month survival rate of patients with high expression of PTEN was 85.59% (P<0.05), of patients with low expression of PTEN it was 94.96% (P<0.05) and in patients with high expression of p27 it was 84.91% (P<0.05). The 36‑month survival rate of patients with low expression of p27 was 94.35% (P<0.05). The survival rates of miRNA‑21, PTEN and p27 low expression groups were significantly higher than those of high expression groups (P<0.05). In conclusion, the expression of miRNA‑21, PTEN and p271 in cancer tissue of NSCLC patients was low. The three indexes have good diagnostic efficacy based on ROC curve analysis, and are expected to be excellent indexes for early clinical diagnosis and prognosis of NSCLC.

View Figures

View References

1	Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins TBK, Veeriah S, Shafi S, Johnson DH, Mitter R, Rosenthal R, et al TRACERx Consortium, : Tracking the evolution of non-small-cell lung cancer. N Engl J Med. 376:2109–2121. 2017. View Article : Google Scholar : PubMed/NCBI
2	Wakelee HA, Chang ET, Gomez SL, Keegan TH, Feskanich D, Clarke CA, Holmberg L, Yong LC, Kolonel LN, Gould MK, et al: Lung cancer incidence in never smokers. J Clin Oncol. 25:472–478. 2007. View Article : Google Scholar : PubMed/NCBI
3	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
4	Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, Znaor A and Bray F: Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 144:1941–1953. 2019. View Article : Google Scholar : PubMed/NCBI
5	Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu Y, Chen Y, Xu L, Zen K, Zhang C, et al: Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol. 28:1721–1726. 2010. View Article : Google Scholar : PubMed/NCBI
6	Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, et al: Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 18:997–1006. 2008. View Article : Google Scholar : PubMed/NCBI
7	Casal-Mouriño A, Valdés L, Barros-Dios JM and Ruano-Ravina A: Lung cancer survival among never smokers. Cancer Lett. 451:142–149. 2019. View Article : Google Scholar : PubMed/NCBI
8	Vitsios DM, Davis MP, van Dongen S and Enright AJ: Large-scale analysis of microRNA expression, epi-transcriptomic features and biogenesis. Nucleic Acids Res. 45:1079–1090. 2017. View Article : Google Scholar : PubMed/NCBI
9	Iorio MV and Croce CM: MicroRNA dysregulation in cancer: Diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med. 4:143–159. 2012. View Article : Google Scholar : PubMed/NCBI
10	Jin X, Chen Y, Chen H, Fei S, Chen D, Cai X, Liu L, Lin B, Su H, Zhao L, et al: Evaluation of tumor-derived exosomal miRNA as potential diagnostic biomarkers for early-stage non-small cell lung cancer using next-generation sequencing. Clin Cancer Res. 23:5311–5319. 2017. View Article : Google Scholar : PubMed/NCBI
11	Xia H, Li Y and Lv X: MicroRNA-107 inhibits tumor growth and metastasis by targeting the BDNF-mediated PI3K/AKT pathway in human non-small lung cancer. Int J Oncol. 49:1325–1333. 2016. View Article : Google Scholar : PubMed/NCBI
12	Xie Y, Naizabekov S, Chen Z and Tokay T: Power of PTEN/AKT: Molecular switch between tumor suppressors and oncogenes. Oncol Lett. 12:375–378. 2016. View Article : Google Scholar : PubMed/NCBI
13	Sharma SS and Pledger WJ: The non-canonical functions of p27 (Kip1) in normal and tumor biology. Cell Cycle. 15:1189–1201. 2016. View Article : Google Scholar : PubMed/NCBI
14	Fenchel K, Sellmann L and Dempke WC: Overall survival in non-small cell lung cancer - what is clinically meaningful? Transl Lung Cancer Res. 5:115–119. 2016.PubMed/NCBI
15	Shepherd L, Ryom L, Law M, Petoumenos K, Hatleberg CI, d'Arminio Monforte A, Sabin C, Bower M, Bonnet F, Reiss P, et al Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group, : Cessation of cigarette smoking and the impact on cancer incidence in human immunodeficiency virus-infected persons: The data collection on adverse events of anti-HIV drugs study. Clin Infect Dis. 68:650–657. 2019. View Article : Google Scholar : PubMed/NCBI
16	Kozub M, Gachewicz B, Kasprzyk M, Roszak M, Gasiorowski L and Dyszkiewicz W: Impact of smoking history on postoperative complications after lung cancer surgery - a study based on 286 cases. Kardiochir Torakochirurgia Pol. 16:13–18. 2019.(In Polish). PubMed/NCBI
17	Sozzi G, Conte D, Leon M, Ciricione R, Roz L, Ratcliffe C, Roz E, Cirenei N, Bellomi M, Pelosi G, et al: Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol. 21:3902–3908. 2003. View Article : Google Scholar : PubMed/NCBI
18	Zhao W, Zhao JJ, Zhang L, Xu QF, Zhao YM, Shi XY and Xu AG: Serum miR-21 level: A potential diagnostic and prognostic biomarker for non-small cell lung cancer. Int J Clin Exp Med. 8:14759–14763. 2015.PubMed/NCBI
19	Ha M and Kim VN: Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 15:509–524. 2014. View Article : Google Scholar : PubMed/NCBI
20	Carthew RW: Gene regulation by microRNAs. Curr Opin Genet Dev. 16:203–208. 2006. View Article : Google Scholar : PubMed/NCBI
21	Zhu H, Chen W, Xu J, Yin L, Zhu H, Liu J, Wang T and He X: MiR-21 expression significance in non-small cell lung cancer tissue and plasma. Int J Clin Exp Med. 10:2918–2924. 2017.
22	Marsit CJ, Zheng S, Aldape K, Hinds PW, Nelson HH, Wiencke JK and Kelsey KT: PTEN expression in non-small-cell lung cancer: Evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. Hum Pathol. 36:768–776. 2005. View Article : Google Scholar : PubMed/NCBI
23	Catzavelos C, Tsao MS, DeBoer G, Bhattacharya N, Shepherd FA and Slingerland JM: Reduced expression of the cell cycle inhibitor p27Kip1 in non-small cell lung carcinoma: A prognostic factor independent of Ras. Cancer Res. 59:684–688. 1999.PubMed/NCBI
24	Liu ZL, Wang H, Liu J and Wang ZX: MicroRNA-21 (miR-21) expression promotes growth, metastasis, and chemo- or radioresistance in non-small cell lung cancer cells by targeting PTEN. Mol Cell Biochem. 372:35–45. 2013. View Article : Google Scholar : PubMed/NCBI
25	Zhang JG, Wang JJ, Zhao F, Liu Q, Jiang K and Yang GH: MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). Clin Chim Acta. 411:846–852. 2010. View Article : Google Scholar : PubMed/NCBI
26	David O: Akt and PTEN: New diagnostic markers of non-small cell lung cancer? J Cell Mol Med. 5:430–433. 2001. View Article : Google Scholar : PubMed/NCBI
27	Arteaga CL: The epidermal growth factor receptor: From mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol. 19 (Suppl):S32–S40. 2001.
28	Yarden Y and Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2:127–137. 2001. View Article : Google Scholar : PubMed/NCBI
29	Wang DD, Ma L, Wong MP, Lee VH and Yan H: Contribution of EGFR and ErbB-3 heterodimerization to the EGFR mutation-induced gefitinib- and erlotinib-resistance in non-small-cell lung carcinoma treatments. PLoS One. 10:e01283602015. View Article : Google Scholar : PubMed/NCBI
30	Xu Y, Zong S, Gao X, Zhang H, Wang B, Li P, Liu T and Li S: Combined treatment of ABT199 and irinotecan suppresses KRAS-mutant lung cancer cells. Gene. 688:1–6. 2019. View Article : Google Scholar : PubMed/NCBI